I don't think they can run a trial designed to address needs of patients that have developed a resistance or mutation to a drug that isn't yet approved. I would think right now they would have to run it against the current standard of care. I could be way off base here.....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.